WCN26-5997 Clinical impact of immunosuppressive combination therapy in MPO-ANCA–associated rapidly progressive glomerulonephritis: a retrospective comparison with steroid monotherapy

Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) predominantly affects elderly individuals and often presents with rapidly progressive glomerulonephritis (RPGN). The standard treatment consists of corticosteroids combined with immunosuppressive agents. However, in elderly patients, adverse events such as severe infections are major concerns, and tailoring treatment intensity is essential.